CeRoo

CeRoo is a preclinical-stage biotechnology company headquartered in Berlin, Germany, specializing in the development of novel phagocytosis checkpoint inhibitors for cancer treatment. The company's core technology focuses on the LRP1 (Low-density lipoprotein receptor-related protein 1) pathway, which acts as a "don't eat me" signal that allows cancer cells to evade the innate immune system. By developing monoclonal antibodies that block this signal, CeRoo aims to trigger the engulfment and destruction of tumor cells by macrophages. Their lead programs target both hematological malignancies, such as acute myeloid leukemia, and various solid tumors. Founded as a spin-off from the Ludwig Maximilian University of Munich, the company is supported by leading venture capital firms including Forbion and High-Tech Gründerfonds.